Multimerization of ERBB2/HER2 specific aptamer leads to improved receptor binding

Biochem Biophys Res Commun. 2015 Sep 18;465(2):218-24. doi: 10.1016/j.bbrc.2015.07.157. Epub 2015 Aug 4.

Abstract

Aptamers represent a promising new treatment modality for cancer. Specificity and high affinity are two parameters that characterize aptamers. In this work, we elucidated physicochemical parameters of an ERBB2/HER2 specific aptamer and determined an optimal multimerization state, leading to higher binding and improved avidity. We applied biochemical, immunochemical and biophysical methodologies to characterize binding behaviors of multimerized versions of an ERBB2/HER2 specific aptamer and demonstrate structural integrity. Finally, we show that the trimeric ERBB2/HER2 specific aptamer instigates no immunogenic response in vivo. In summary, the set of methodologies we employed establishes a way to enhance activity of a model HER2-aptamer.

Keywords: Aptamer; ERBB2/HER2; Multimerization.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Agents / chemical synthesis
  • Antineoplastic Agents / immunology
  • Aptamers, Nucleotide / administration & dosage*
  • Aptamers, Nucleotide / chemical synthesis
  • Aptamers, Nucleotide / immunology
  • Base Sequence
  • Cell Line, Tumor
  • Gene Expression
  • Humans
  • Immune Tolerance*
  • Immunity, Cellular / drug effects
  • Immunity, Humoral / drug effects
  • Mice
  • Mice, Inbred BALB C
  • Molecular Sequence Data
  • Polymerization*
  • Protein Binding
  • Receptor, ErbB-2 / antagonists & inhibitors*
  • Receptor, ErbB-2 / genetics
  • Receptor, ErbB-2 / metabolism

Substances

  • Antineoplastic Agents
  • Aptamers, Nucleotide
  • ERBB2 protein, human
  • Receptor, ErbB-2